CA3064464A1 - Corticotropin releasing factor receptor antagonists - Google Patents

Corticotropin releasing factor receptor antagonists Download PDF

Info

Publication number
CA3064464A1
CA3064464A1 CA3064464A CA3064464A CA3064464A1 CA 3064464 A1 CA3064464 A1 CA 3064464A1 CA 3064464 A CA3064464 A CA 3064464A CA 3064464 A CA3064464 A CA 3064464A CA 3064464 A1 CA3064464 A1 CA 3064464A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
solvate
acceptable salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3064464A
Other languages
English (en)
French (fr)
Inventor
Alexis HOWERTON
Hal GERBER
Michael Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spruce Biosciences Inc
Original Assignee
Spruce Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65362494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3064464(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Spruce Biosciences Inc filed Critical Spruce Biosciences Inc
Publication of CA3064464A1 publication Critical patent/CA3064464A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3064464A 2017-08-14 2018-08-14 Corticotropin releasing factor receptor antagonists Pending CA3064464A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545406P 2017-08-14 2017-08-14
US62/545,406 2017-08-14
PCT/US2018/046760 WO2019036503A1 (en) 2017-08-14 2018-08-14 CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
CA3064464A1 true CA3064464A1 (en) 2019-02-21

Family

ID=65362494

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3064464A Pending CA3064464A1 (en) 2017-08-14 2018-08-14 Corticotropin releasing factor receptor antagonists

Country Status (11)

Country Link
US (9) US20210361664A1 (cg-RX-API-DMAC7.html)
EP (1) EP3628005A4 (cg-RX-API-DMAC7.html)
JP (3) JP7398963B2 (cg-RX-API-DMAC7.html)
KR (2) KR20200040761A (cg-RX-API-DMAC7.html)
CN (2) CN110996943A (cg-RX-API-DMAC7.html)
AU (2) AU2018317398A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020002967A2 (cg-RX-API-DMAC7.html)
CA (1) CA3064464A1 (cg-RX-API-DMAC7.html)
EA (1) EA202090450A1 (cg-RX-API-DMAC7.html)
MX (2) MX2019015320A (cg-RX-API-DMAC7.html)
WO (1) WO2019036503A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE068315T2 (hu) 2014-01-21 2024-12-28 Neurocrine Biosciences Inc CRF1 receptor antagonisták kongenitális adrenális hiperplázia kezelésére
BR112020002967A2 (pt) 2017-08-14 2020-08-11 Spruce Biosciences, Inc. antagonistas de receptor de fator de liberação de corticotropina
EP4438124A3 (en) * 2018-04-27 2024-12-18 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
TW202446384A (zh) 2018-12-07 2024-12-01 美商紐羅克里生物科學有限公司 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式
JP2022541550A (ja) * 2019-07-19 2022-09-26 スプルース バイオサイエンシーズ，インク． 先天性副腎過形成を処置する方法
CA3152590A1 (en) 2019-09-27 2021-04-01 Evan Smith Crf receptor antagonists and methods of use
EP4175572A4 (en) 2020-08-12 2024-03-27 Spruce Biosciences, Inc. Methods and compositions for treating polycystic ovary syndrome
US20240024330A1 (en) * 2020-08-26 2024-01-25 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2025188842A1 (en) * 2024-03-08 2025-09-12 Spruce Biosciences, Inc. Amorphous solid dispersion of tildacerfont formulations

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990067704A (ko) 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
DE69736513T2 (de) 1996-02-07 2007-04-05 Neurocrine Biosciences, Inc., San Diego Pyrazolopyrimidine als crf rezeptor-antagonisten
HU228962B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo triazines, pharmaceutical compositions containing them and use of the compounds
SI9720045B (sl) 1996-07-24 2008-02-29 Bristol Myers Squibb Pharma Co Azolo triazini in pirimidini
ES2273369T3 (es) 1996-08-28 2007-05-01 Pfizer Inc. Derivados 6,5 heterobiciclicos sustituidos.
IL137019A (en) 1998-01-28 2010-11-30 Du Pont Pharm Co 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them
EP1049699B1 (en) 1998-01-28 2004-04-21 Bristol-Myers Squibb Pharma Company Pyrazolotriazines as crf antagonists
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
JP2003510326A (ja) 1999-09-30 2003-03-18 ニューロジェン・コーポレーション アミノ置換ピラゾロ［１，５−ａ］−１，５−ピリミジン類及びピラゾロ［１，５−ａ］−１，３，５−トリアジン類
BR0008059A (pt) 1999-12-08 2002-03-26 Pharmacia Corp Composições de valdecoxib
RS50863B (sr) 2001-03-13 2010-08-31 Bristol-Myers Squibb Pharma Company 4-(2-butilamino)-2,7-dimetil-8-(2-metil-6-metoksipirid-3-il) pirazolo/1,5a/-1,3,5-triazin,njegovi enantiomeri i farmaceutski prihvatljive soli kao ligandi receptora za faktor koji oslobađa kortikotropin
WO2005020910A2 (en) 2003-08-27 2005-03-10 Pharmacia Corporation Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries
PL1708790T3 (pl) 2003-12-02 2010-10-29 Pharmaneuroboost N V Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych
NZ547990A (en) 2003-12-22 2010-04-30 Smithkline Beecham Cork Ltd CRF receptor antagonists and methods relating thereto
CN1917882A (zh) 2004-02-13 2007-02-21 辉瑞产品公司 非典型抗精神病药物与促肾上腺皮质激素释放因子拮抗剂的治疗剂组合
EP1722826A2 (en) 2004-02-13 2006-11-22 SB Pharmco Puerto Rico Inc. Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses
EP1781257B1 (en) * 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
EP1869049B1 (en) 2005-03-21 2009-03-04 Eli Lilly And Company Imidazopyridazine compounds
CN101516835A (zh) 2006-07-19 2009-08-26 俄亥俄州立大学研究基金会 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途
MX2009003098A (es) 2006-09-20 2009-04-01 Lilly Co Eli Compuestos de tiofen pirazolopirimidina.
AU2007297421B2 (en) 2006-09-20 2012-03-08 Eli Lilly And Company Thiazole pyrazolopyrimidines as CRF1 receptor antagonists
US8952207B2 (en) 2007-09-11 2015-02-10 The University Of Houston System Copper-catalyzed C—H bond arylation
WO2009035473A2 (en) 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
SI2350079T1 (sl) 2008-10-02 2013-02-28 Eli Lilly And Company Spojine tiazolil-pirazolopirimidina kot sintetiäśni intermediati in sorodni sintezni postopki
EP3486648B1 (en) * 2008-12-24 2025-04-30 Quest Diagnostics Investments Incorporated Mass spectrometry assay for congenital adrenal hyperplasia
PT2519230T (pt) * 2009-12-31 2019-01-18 Marius Pharmaceuticals Llc Modulação de solubilidade, estabilidade, absorção, metabolismo e perfil farmacocinético de fármacos lipofílicos por esteróis
WO2013134548A2 (en) 2012-03-08 2013-09-12 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
US20150094310A1 (en) 2012-04-23 2015-04-02 Holsboermaschmeyer Neurochemie Gmbh Crhr1 antagonists for use in the treatment of patients having crh overactivity
HUE068315T2 (hu) * 2014-01-21 2024-12-28 Neurocrine Biosciences Inc CRF1 receptor antagonisták kongenitális adrenális hiperplázia kezelésére
WO2016161011A1 (en) 2015-03-31 2016-10-06 Ziva Medical, Inc. Methods and systems for the manipulation of ovarian tissues
WO2019036472A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
BR112020002967A2 (pt) 2017-08-14 2020-08-11 Spruce Biosciences, Inc. antagonistas de receptor de fator de liberação de corticotropina
EP4438124A3 (en) 2018-04-27 2024-12-18 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
TW202446384A (zh) 2018-12-07 2024-12-01 美商紐羅克里生物科學有限公司 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式
US20200255436A1 (en) 2019-02-12 2020-08-13 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
JP2022541550A (ja) 2019-07-19 2022-09-26 スプルース バイオサイエンシーズ，インク． 先天性副腎過形成を処置する方法
EP4175572A4 (en) 2020-08-12 2024-03-27 Spruce Biosciences, Inc. Methods and compositions for treating polycystic ovary syndrome
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
EP4402142A4 (en) 2021-11-19 2025-07-23 Spruce Biosciences Inc CRYSTALLINE COMPOSITION OF TILDACERFONT AND ITS METHODS OF USE AND PREPARATION

Also Published As

Publication number Publication date
US20210015827A1 (en) 2021-01-21
US12115166B2 (en) 2024-10-15
WO2019036503A1 (en) 2019-02-21
MX2019015320A (es) 2020-07-20
EP3628005A1 (en) 2020-04-01
US11344557B2 (en) 2022-05-31
US20210361664A1 (en) 2021-11-25
JP7573080B2 (ja) 2024-10-24
EP3628005A4 (en) 2021-01-20
US11311549B2 (en) 2022-04-26
KR20250022913A (ko) 2025-02-17
MX2023000501A (es) 2023-02-13
CN110996943A (zh) 2020-04-10
AU2018317398A1 (en) 2019-11-21
AU2023200189A1 (en) 2023-02-16
US20210322431A1 (en) 2021-10-21
US20210038609A1 (en) 2021-02-11
US20230321112A1 (en) 2023-10-12
US11351177B2 (en) 2022-06-07
JP2024001014A (ja) 2024-01-09
JP2025020148A (ja) 2025-02-12
EA202090450A1 (ru) 2020-09-24
US20230414627A1 (en) 2023-12-28
JP7398963B2 (ja) 2023-12-15
US20190262349A1 (en) 2019-08-29
JP2020530831A (ja) 2020-10-29
US20210322430A1 (en) 2021-10-21
KR20200040761A (ko) 2020-04-20
AU2023200189B2 (en) 2024-02-22
US20220143037A1 (en) 2022-05-12
US11007201B2 (en) 2021-05-18
CN118845788A (zh) 2024-10-29
BR112020002967A2 (pt) 2020-08-11
US10849908B2 (en) 2020-12-01

Similar Documents

Publication Publication Date Title
AU2023200189B2 (en) Corticotropin releasing factor receptor antagonists
AU2023201703B2 (en) Corticotropin releasing factor receptor antagonists
US20240261300A1 (en) Methods of treating congenital adrenal hyperplasia
US20200255436A1 (en) Corticotropin releasing factor receptor antagonists

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240214